Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Akebia Therapeutics (AKBA) over the last 9 years, with Q3 2025 value amounting to $77000.0.

  • Akebia Therapeutics' Capital Expenditures rose 375000.0% to $77000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $223000.0, marking a year-over-year increase of 61935.48%. This contributed to the annual value of $33000.0 for FY2024, which is N/A changed from last year.
  • Latest data reveals that Akebia Therapeutics reported Capital Expenditures of $77000.0 as of Q3 2025, which was up 375000.0% from $126000.0 recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Capital Expenditures registered a high of $126000.0 during Q2 2025, and its lowest value of $2000.0 during Q3 2024.
  • Over the past 4 years, Akebia Therapeutics' median Capital Expenditures value was $44000.0 (recorded in 2021), while the average stood at $53375.0.
  • Per our database at Business Quant, Akebia Therapeutics' Capital Expenditures surged by 9322.03% in 2022 and then soared by 375000.0% in 2025.
  • Over the past 4 years, Akebia Therapeutics' Capital Expenditures (Quarter) stood at $59000.0 in 2021, then soared by 93.22% to $114000.0 in 2022, then crashed by 98.25% to $2000.0 in 2024, then skyrocketed by 3750.0% to $77000.0 in 2025.
  • Its Capital Expenditures was $77000.0 in Q3 2025, compared to $126000.0 in Q2 2025 and $18000.0 in Q1 2025.